最高の悪性黒色腫医師 - トップ89名の医師

900件以上の黒色腫処置を実施 – ビュレント・カラゴズ医師は、アナドル医療センターにて免疫療法および分子標的療法を専門としています。

• 33年の経験 の腫瘍内科診療経験
• イスタンブール・オカン大学医学部 教授
• トルコ腫瘍内科学会 会員
• がん研究分野における学術論文40件以上を発表

Eda Tanrikulu教授は転移性悪性黒色腫を専門とし、アナドル医療センターにおけるがん症例評価においてリーダーシップを発揮しています。

• 腫瘍内科の専門医資格を有し、21年の経験以上の臨床経験を持つ
• トルコ腫瘍内科専門医試験において全国3位を獲得
• 腫瘍学における国際臨床研究を主導
• ハイダルパシャ・ヌムネ病院にて主任研究員を歴任

Mustafa Solak氏は、ヒサール・インターコンチネンタル病院にて、黒色腫を含む1,100件以上のがん治療を実施しています。

• 腫瘍学における20年の経験の経験
• ハジェテペ大学がん研究所にて研修
• テキサス大学MDアンダーソンがんセンターに勤務
• 黒色腫を含むさまざまながんを専門とする

Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.

Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

ガレニア病院にて、メラノーマ治療を専門とする外科腫瘍学の認定専門医。

• メラノーマに重点を置いた外科腫瘍学を専門とする
• 2030年までConacem認定取得
• メキシコ腫瘍学会（SMEO）会員
• 2020年よりアナワク大学にて大学教員として従事

メリムスキー教授は、スーラスキー医療センターの軟部組織・骨腫瘍科を率い、肉腫およびメラノーマの専門診療において41年の経験以上の経験を有しています。

• ワイツマン科学研究所・腫瘍免疫学研究室 上級研究員
• ESMO 肉腫・骨腫瘍部門 ファカルティメンバー
• ヨーロッパ最高峰の肉腫センターであるギュスターヴ・ルッシー研究所にて研鑽
• 抗メラノーマ抗体に関する修士論文を発表

Head of Teaching at the Puerto Vallarta Regional Hospital

2020-2023

Medical records manager at the Regional Hospital of Puerto Vallarta 2 months 2020

General practitioner in private medical office

2015-2022

Doctor in charge of weight control clinic

2013-2014

Medical assistant in dermatology clinic

2008-2013

Medical Assistant in Dermatological procedures.

 Medical Assistant in minimally invasive surgical procedures

 Operation of fractional laser machine - IPIXEL-ER and

facial rejuvenation with IPL.

 Experience in laser hair removal with Intense Pulsed Light and

radiofrequency

 Experience with ultrasonic cavitation

 Experience with ultraviolet (UV) light phototherapy machine for the

treatment of psoriasis and vitiligo.

 Experience assisting in Botox and Fillers procedures.

 Biomagnet certified by the Higher Institute of Biomagnetism

doctor ISAAC GOIZ DURAN

 Experience in clinical records

 Training in continuing education and professional development of teachers

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Activities • Prevention, research and early diagnosis of cancer • Palliative care in cancer • Cytotoxic chemotherapy • Hormontherapy • Targeted treatment • Immunotherapy Education • 2004 -2010 - Istanbul University, Istanbul faculty of medicine • 2011-2015 - Istanbul University, Istanbul faculty of medicine, internal medicine specialist • 2013-2014 - Cleveland Clinic Endocrinology Department, research associate • 2016-2019 Bezmiâlem Foundation University Medical Oncology Subdivision • Dissertation: Prognostic value of absolute monocyte count in patients with mantle cell lymphoma. • Subdivision Dissertation: An effect of adjuvant chemotherapy on lipid profile and anthropometric parameters in patients with breast and colon cancer. Publications • Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma. Aliyev A, Gupta M, et al. Endocr  18. • The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. • Aliyev A, Soundararajan S, Bucak E et al. Surgery.  • Diagnostic accuracy of circulating thyrotropin receptor messenger RNA combined with neck ultrasonography in patients with Bethesda III-V thyroid cytology. Aliyev A, Patel J, Brainard J, et al. Surgery.2016 Jan;159(1):113-7. doi: 10.1016/j.surg.2015.06.063. Epub 2015 Oct 9. • Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients. Seker M, Aliyev A, et al. Oncol Res Treat. Epub 2018 Aug 20. • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Aliyev A. Cancer Chemother Pharmacol.2019 Jan; Epub 2018 Oct 30. • Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Turk HM, Aliyev A, Celik RS. Curr Probl Cancer.2019 Jul 29. pii: currproblcancer.2019.06.009. • Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience. Tarik Demir, Murat Araz, Altay Aliyev. Medicine Science International Medicine Journal. • Oral presentations 

• Education: 
•  
• 2001-2007: University of Ioannina Medical School, Greece.
• 2007: Degree in Medicine.
• 2013: Doctoral degree from the Medical School of the Johann Wolfgang Goethe University, Frankfurt (Dr. Med)
• 09.2016 – Today: Master’s in Healthcare Business Studies.

Professional experience:

04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach

05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach

• 01.2016 – 06.2017: Senior physician in the Department of interventional Radiation Oncology, Medical Center Athens
•  
• 07.2017 – Today: Head of the Department of Radiation Oncology at the German Oncology Center, Limassol, Cyprus.

シナン・カラアスラン医師は、アナドル・メディカルセンターの腫瘍内科医です（2014年より在籍）。乳癌、大腸癌、泌尿生殖器系腫瘍の治療を専門とし、腫瘍内科における臨床経験は2003年より積んでいます。トルコ医師会、トルコ腫瘍内科学会、トルコ肺癌学会の会員です。

患者様がカラアスラン医師を選び、信頼する理由：

• 乳癌・大腸癌・泌尿生殖器系腫瘍の難症例を担当し、腫瘍の種類と病期に応じた最新の全身療法を適用しています。
• トルコ医師会、トルコ腫瘍内科学会、トルコ肺癌学会の会員です。
• 化学療法および免疫療法に関する多数の学術論文および患者向け教育資料の著者です。
• 同医師が勤務するセンターはESMO指定センターの認定を受け、JCI認証を取得しており、米国の主要医療機関の一つであるジョンズ・ホプキンス・メディシン・インターナショナルと戦略的提携を結んでいます。患者様にとって、これは米国の診療プロトコルに基づく治療と最新医療機器の活用を意味します。

900件以上の治療実績 – セルカン・ケシキン医師は、進行期黒色腫治療を専門とする高評価の腫瘍内科医です。

• トルコ腫瘍内科専門医資格試験で第1位を獲得
• 国際腫瘍学専門誌に42本の論文を発表
• 世界有数の腫瘍学学会であるASCOおよびESMOの会員
• 25年の経験 の複雑ながん症例の診療経験
• 化学療法、免疫療法、および分子標的療法の専門家

イェシム・ユルドゥルム教授は、がん免疫療法および分子標的治療を専門とし、80を超える国際学術論文および共著書籍を有しています。

• 欧州臨床腫瘍学会（ESMO）会員
• マウント・バーノン・キャンサーセンターにてメラノーマおよび腎臓がんクリニックの研修を修了
• イスタンブール・ハリチ大学教授
• アナドル医療センターにて22年の経験の診療経験

Oncologist, Specialist in skin cancer treatment

シェレフ・ケミュルキュ教授は、ECFMG及びESMO認定の乳腺腫瘍専門医であり、20年以上の診療経験を有しています。固形がん、乳がん、大腸がん、肺がんの治療を専門とし、キャリアを通じて教育・研究職を歴任してきました。複数の専門職能団体の会員でもあります。

Prof. Haluk Duman is an expert plastic surgeon based in Istanbul, Turkey with over 35 years of experience. He specializes in plastic surgery after cancer, burns, and skin tumors, as well as hand and maxillofacial surgery. He has a general medical degree from Istanbul University Medical Faculty and specialty in plastic and reconstructive surgery from Ankara GATA Medical School, and a fellowship from The University of Texas MD Anderson Cancer Center. Prof. Duman has published over 60 papers and participated in 100+ conferences. He is a member of various organizations.

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.